Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2019

01-02-2019 | Endocrine Tumors

Completion Thyroidectomy: Revisited a Quarter of a Century Later

Authors: Benzon M. Dy, MD, Veljko Strajina, MD, Michael Tuttle, MD, Ashok R. Shaha, MD

Published in: Annals of Surgical Oncology | Issue 2/2019

Login to get access

Excerpt

The excellent outcome for patients with thyroid cancer is increasingly recognized, with Japan and the United States considerably interested in observing selected microcarcinomas.1,2 In the last decade, our experience has shown that most thyroid microcarcinomas can be observed safely.3 It therefore is understandable why the potential overtreatment of thyroid cancer has been debated, not only among professionals, but also in the media and general public. …
Literature
1.
Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34:28–35.CrossRefPubMed
2.
Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27–34.CrossRefPubMedPubMedCentral
3.
Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg. 2017;143:1015–20.CrossRefPubMedPubMedCentral
4.
Ritter K, Elfenbein D, Schneider DF, Chen H, Sippel RS. Hypoparathyroidism after total thyroidectomy: incidence and resolution. J Surg Res. 2015;197:348–53.CrossRefPubMedPubMedCentral
5.
Asari R, Passler C, Kaczirek K, Scheuba C, Niederle B. Hypoparathyroidism after total thyroidectomy: a prospective study. Arch Surg. 2008;143:132–7; discussion 138.
6.
Su A, Wang B, Gong Y, Gong R, Li Z, Zhu J. Risk factors of hypoparathyroidism following total thyroidectomy with central lymph node dissection. Med Baltimore. 2017;96:e8162.CrossRef
7.
Kim SM, Kim HK, Kim KJ, et al. Recovery from permanent hypoparathyroidism after total thyroidectomy. Thyroid. 2015;25:830–33.CrossRefPubMed
8.
Shaha AR, Jaffe BM. Completion thyroidectomy: a critical appraisal. Surgery. 1992;112:1148–52; discussion 1152–43.
9.
Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–81; discussion 381–74.
10.
Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124:958–64; discussion 964–56.
11.
Adam MA, Pura J, Goffredo P, et al. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. J Clin Endocrinol Metab. 2015;100:115–21.CrossRefPubMed
12.
Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well-differentiated intrathyroid malignancy. Surgery. 2012;151:571–79.CrossRefPubMed
13.
Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery. 1999;126:13–9.CrossRefPubMed
14.
Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9:421–27.CrossRefPubMed
15.
Nixon IJ, Patel SG, Palmer FL, et al. Selective use of radioactive iodine in intermediate-risk papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2012;138:1141–46.CrossRefPubMed
16.
Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144:980–7; discussion 987–8.
17.
Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–85.CrossRefPubMed
18.
Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–57; discussion 1057–58.
19.
Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116:1036–40; discussion 1040–31.
20.
Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53.PubMed
21.
Cranshaw IM, Carnaille B. Micrometastases in thyroid cancer: an important finding? Surg Oncol. 2008;17:253–58.CrossRefPubMed
22.
Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid: prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31–40.CrossRefPubMed
23.
24.
Paphavasit A, Thompson GB, Hay ID, et al. Follicular and Hurthle cell thyroid neoplasms: is frozen-section evaluation worthwhile? Arch Surg. 1997;132:674–78; discussion 678–80.
25.
Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL. Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. Ann Surg. 2001;233:716–22.CrossRefPubMedPubMedCentral
26.
American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.
Metadata
Title
Completion Thyroidectomy: Revisited a Quarter of a Century Later
Authors
Benzon M. Dy, MD
Veljko Strajina, MD
Michael Tuttle, MD
Ashok R. Shaha, MD
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-07102-z

Other articles of this Issue 2/2019

Annals of Surgical Oncology 2/2019 Go to the issue

Breast Oncology

Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy

Pancreatic Tumors

Increased SOX9 Expression in Premalignant and Malignant Pancreatic Neoplasms

Hepatobiliary Tumors

Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis

Endocrine Tumors

Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?

Gastrointestinal Oncology

Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Breast Oncology

Regional Recurrence Risk Following a Negative Sentinel Node Procedure Does Not Approximate the False-Negative Rate of the Sentinel Node Procedure in Breast Cancer Patients Not Receiving Radiotherapy or Systemic Treatment